Eli Lilly

Site Solutions Summit honors Eli Lilly, PPD with Eagle Awards

Wednesday, October 20, 2010 02:19 PM

The complexity of today’s clinical trials, the regulatory burdens and the disease states being tackled make the current drug discovery market a difficult one in which to operate, Dr. Jeffrey Kasher, vice president of clinical development organization for Lilly Research Laboratories at Eli Lilly, told more than 350 industry members last Saturday evening at the Site Solutions Summit in Clearwater Beach, Fla.

More... »

More big pharmaceuticals join trend of partnering with CROs to cut costs, speed drug development

Monday, October 11, 2010 10:27 AM

Major pharmaceutical companies are increasingly forming long-term, strategic partnerships with a small number of global contract research organizations (CROs) in order to cut costs and streamline their outsourced clinical work.

More... »

Eli Lilly expands its outsourcing partnership with i3 Statprobe

Tuesday, September 28, 2010 07:40 AM

Expanding the outsourcing support of its clinical trials, Eli Lilly is transferring U.S. medical writing and biostatistical services to i3 Statprobe, a move that expands the business relationship formed between the two companies in 2008 when Lilly transferred the majority of its domestic data management activities to i3.

More... »

PPD Names CIO and EVP for Global Clinical Development

Monday, June 21, 2010 09:45 AM

Contract research organization PPD appointed Mike Wilkinson, Ph.D., as executive vice president and chief information officer and Paul Colvin as executive vice president of global clinical development.

More... »

Covance Launches Discovery and Translational Services Division

Monday, May 17, 2010 12:59 PM

Covance has reorganized its early-stage drug development work into a new division dedicated to discovery services, antibody products and immunology. The new group, Discovery and Translational Services, integrates the CRO’s Biomarker Center for Excellence, formed in 2009, with its Genomics Laboratory and existing partnerships with Caprion Proteomics and Rules-Based Medicine. 

More... »

Covance to Close Preclinical Site

Tuesday, April 20, 2010 06:41 AM

Covance is closing a testing site in Kalamazoo, Mich., as part of the CRO’s ongoing efforts to cut back its preclinical services. The site will be closed by November, and, according to published reports, 63 workers will lose their jobs.

More... »

Covance-Lilly Deal Continues to Bloom

Monday, March 15, 2010 06:51 AM

A little more than a year after Covance entered into a ground-breaking $1.6-billion drug development agreement with Eli Lilly, the contract research organization (CRO) continues to reap the awards of that deal and recently expanded the relationship.

More... »

Covance to Expand Food Safety Services with New Lab, Kellogg Contract

Monday, December 14, 2009 06:14 AM

Covance plans to invest $14 million in a nutritional chemistry and food safety laboratory in Michigan as part of an effort to expand the contract research organization’s (CRO’s) food safety testing capabilities. The CRO also entered into a seven-year, $42-million contract with Kellogg Company, which will be an anchor client to Covance’s new facility.

More... »

ICON Extends Lilly Strategic Agreement to Japan

Thursday, November 12, 2009 07:45 AM

ICON has signed an extension to its strategic agreement with Eli Lilly and Company to manage the company’s clinical data management outside the U.S. This extension means that ICON will now also manage Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia, which was originally agreed to in November 2008.

More... »

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

More... »